Fluorogenic Peptide Substrates for Plague Protease Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack specific substrates and inhibitors for the plague plasminogen activator, a key virulence factor of Yersinia pestis, which is essential for detecting the bacterium and controlling plague infections, particularly in cases of antibiotic-resistant strains.
Innovation Solution
Development of substrates and inhibitors specific to the omptin family of bacterial proteases, including peptide sequences with modified N-terminal or C-terminal residues, which can be used to detect enzymatic activity and inhibit the plague plasminogen activator, thereby addressing the infection caused by Yersinia pestis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional detection methods are used for Yersinia pestis, then detection can be performed, but the methods lack specificity for plasminogen activator activity and are slow
Solution Approach 1:
The patent replaces traditional mechanical/cultural detection methods with a biochemical assay system using fluorogenic substrates. The specific substrate SEQ ID NO: 5 (Arg-Arg-Ile-Asn-Arg-Glu) is cleaved by plasminogen activator, producing a fluorescent signal that can be detected rapidly and specifically, eliminating the need for time-consuming culture methods while achieving high detection specificity.
2Reliability
If antibiotics are used to treat Yersinia pestis infection, then treatment can be provided, but antibiotic-resistant strains cannot be controlled
Solution Approach 1:
The patent extracts and targets the specific virulence mechanism (plasminogen activator enzyme) rather than using broad-spectrum antibiotics. By designing inhibitors that specifically bind to and block the plasminogen activator's active site, the treatment effectively neutralizes the bacterium's ability to cause disease while avoiding the resistance issues associated with traditional antibiotic therapy.
Solution Approach 2:
The patent changes the therapeutic parameter from general antimicrobial action to specific enzymatic inhibition. The inhibitor molecules are designed with specific amino acid sequences that match the plasminogen activator's substrate binding site, creating a highly specific interaction that prevents the enzyme from converting plasminogen to plasmin, thereby blocking the virulence mechanism regardless of antibiotic resistance status.
3Ease of operation
If plasminogen activator activity is not specifically detected, then general detection methods can be used, but targeted therapeutic intervention is not possible
Solution Approach 1:
The patent introduces fluorogenic substrate intermediates (SEQ ID NO: 5 and related variants) that serve as mediators between the plasminogen activator enzyme and the detection system. These substrates are simple to use (requiring only incubation and fluorescence measurement) yet provide the specific information needed to confirm plasminogen activator presence and activity, enabling subsequent targeted therapeutic intervention.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The specific substrates and inhibitors enable direct detection of plasminogen activator activity and inhibit its function, providing a targeted therapeutic approach effective against Yersinia pestis infections, including antibiotic-resistant strains, with potential for rapid diagnosis and treatment.
Implementation Method 1
measuring cleavage of the substrate by the protease, thereby detecting the enzymatic activity of omptin family of bacterial proteases
Data Source
AI summary
The present invention is directed to peptide sequences that were identified from combinatorial libraries and could serve as substrates of plague plasminogen activator (Pla). Another aspect of the present invention is drawn to peptides derived from the substrates for Pla as a result of chemical modifications leading to specific inactivation of the proteolytic activity of Pla. Additionally, the present invention is directed to the use of the substrates identified herein in the detection of bacteria expressing omptin family of proteases which includes Y. pestis. Furthermore, the present invention is also directed to the use of the inhibitors identified herein in the prevention and treatment of infection caused by these bacteria.